Investor Overview

Corporate Profile
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Company’s NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Company’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Company’s NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Company’s third-party licensees.
RGNX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$19.85
Change (%) Stock is Down 0.1 (0.50%)
Volume15,333
Data as of 08/21/17 9:37 a.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: RGNX.O.  Currently trading at $19.85 with a 52 week high of $24.55 and a 52 week low of $11.35.
Recent NewsMore >>
DateTitle 
08/11/17REGENXBIO to Present on RGX-314 Gene Therapy Program for Wet AMD at 35th Annual Scientific Meeting of the American Society of Retina Specialists
RGX-314 trial design and subretinal delivery overview to be presented Enrollment continues in RGX-314 Phase I clinical trial for wet AMD; interim update anticipated by year-end 2017 ROCKVILLE, Md., Aug. 11, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, will present at the 35th Annual Scientific Meeting of the Am... 
Printer Friendly Version
08/08/17REGENXBIO Reports Second Quarter 2017 Financial Results and Recent Operational Highlights
Enrollment continues in RGX-314 Phase I clinical trial for wet AMD; interim update anticipated by year-end 2017 Enrollment continues in RGX-501 Phase I/II clinical trial for HoFH; interim update anticipated by year-end 2017 IND active for third lead product candidate – RGX-111 for MPS I $209 million in cash, cash equivalents and marketable securities as of June 30, 2017 ROCKVILLE, Md., Aug. 08, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechn... 
Printer Friendly Version
08/08/17REGENXBIO Announces IND Active for Phase I Trial of RGX-111 to Treat Mucopolysaccharidosis Type I
Clinical trial expected to enroll children and adults with MPS I Anticipate beginning trial enrollment during the first half of 2018ROCKVILLE, Md., August 8, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the Investigational New Drug application (IND) is active for the planned multi-center, open-label, mu... 
Printer Friendly Version
08/01/17REGENXBIO to Host Conference Call on August 8 to Discuss Second Quarter 2017 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Aug. 01, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, August 8, 2017 at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2017 and recent operational highlights. To access the live call by phone, dial (855) 4... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Presentations
DateTitle
08/08/17
Corporate PresentationDownload Documentation 
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever REGENXBIO posts new information to the site. Just enter your e-mail address and click Submit.